Estabrook Capital Management’s AbbVie ABBV Stock Holding History

Estabrook Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.77M	Hold	12,721	–	–	0.4%	55
2025 Q4	$2.91M	Sell	12,721 -242	-2%	-$55.1K	0.43%	55
2025 Q3	$3M	Sell	12,963 -155	-1%	-$31.6K	0.44%	56
2025 Q2	$2.43M	Sell	13,118 -485	-4%	-$90.1K	0.37%	58
2025 Q1	$2.85M	Sell	13,603 -1,240	-8%	-$241K	0.46%	51
2024 Q4	$2.64M	Sell	14,843 -430	-3%	-$79.1K	0.41%	56
2024 Q3	$3.02M	Sell	15,273 -250	-2%	-$46.7K	0.45%	53
2024 Q2	$2.66M	Hold	15,523	–	–	0.41%	56
2024 Q1	$2.83M	Hold	15,523	–	–	0.44%	57
2023 Q4	$2.41M	Sell	15,523 -467	-3%	-$68.1K	0.39%	59
2023 Q3	$2.38M	Sell	15,990 -832	-5%	-$122K	0.42%	57
2023 Q2	$2.27M	Hold	16,822	–	–	0.38%	61
2023 Q1	$2.68M	Hold	16,822	–	–	0.47%	56
2022 Q4	$2.72M	Sell	16,822 -50	-0.3%	-$7.67K	0.47%	57
2022 Q3	$2.26M	Sell	16,872 -340	-2%	-$48.8K	0.42%	58
2022 Q2	$2.64M	Buy	17,212 +502	+3%	+$76.7K	0.45%	58
2022 Q1	$2.71M	Sell	16,710 -1,874	-10%	-$272K	0.4%	62
2021 Q4	$2.52M	Sell	18,584 -11	-0.1%	-$1.3K	0.36%	65
2021 Q3	$2.01M	Sell	18,595 -1,729	-9%	-$198K	0.32%	67
2021 Q2	$2.29M	Sell	20,324 -3,903	-16%	-$440K	0.35%	64
2021 Q1	$2.62M	Buy	24,227 +3	+0%	+$321	0.4%	61
2020 Q4	$2.6M	Buy	24,224 +4,766	+24%	+$458K	0.43%	60
2020 Q3	$1.7M	Buy	19,458 +10,958	+129%	+$1.03M	0.31%	63
2020 Q2	$835K	Buy	8,500 +6	+0.1%	+$528	0.16%	71
2020 Q1	$647K	Buy	8,494 +11	+0.1%	+$937	0.14%	78
2019 Q4	$751K	Sell	8,483 -198	-2%	-$16.4K	0.11%	85
2019 Q3	$657K	Buy	8,681 +24	+0.3%	+$1.65K	0.11%	90
2019 Q2	$630K	Sell	8,657 -500	-5%	-$39.3K	0.1%	92
2019 Q1	$738K	Sell	9,157 -3,907	-30%	-$320K	0.12%	82
2018 Q4	$1.2M	Sell	13,064 -3,495	-21%	-$307K	0.22%	68
2018 Q3	$1.57M	Sell	16,559 -2,450	-13%	-$232K	0.24%	68
2018 Q2	$1.76M	Sell	19,009 -1,200	-6%	-$117K	0.28%	66
2018 Q1	$1.91M	Sell	20,209 -200	-1%	-$22K	0.3%	64
2017 Q4	$1.97M	Sell	20,409 -93	-0.5%	-$8.77K	0.3%	62
2017 Q3	$1.82M	Sell	20,502 -400	-2%	-$30.4K	0.28%	63
2017 Q2	$1.52M	Sell	20,902 -100	-0.5%	-$6.72K	0.24%	70
2017 Q1	$1.37M	Sell	21,002 -1,100	-5%	-$69.2K	0.21%	71
2016 Q4	$1.38M	Sell	22,102 -850	-4%	-$51.9K	0.22%	72
2016 Q3	$1.45M	Sell	22,952 -100	-0.4%	-$6.47K	0.21%	70
2016 Q2	$1.43M	Sell	23,052 -890	-4%	-$54.2K	0.21%	68
2016 Q1	$1.37M	Hold	23,942	–	–	0.2%	69
2015 Q4	$1.42M	Sell	23,942 -100	-0.4%	-$5.76K	0.21%	68
2015 Q3	$1.31M	Sell	24,042 -100	-0.4%	-$6.51K	0.19%	70
2015 Q2	$1.62M	Sell	24,142 -150	-0.6%	-$9.79K	0.2%	70
2015 Q1	$1.42M	Sell	24,292 -2,500	-9%	-$151K	0.17%	73
2014 Q4	$1.75M	Sell	26,792 -970	-3%	-$61.2K	0.19%	67
2014 Q3	$1.6M	Sell	27,762 -40	-0.1%	-$2.22K	0.17%	69
2014 Q2	$1.57M	Sell	27,802 -9,870	-26%	-$518K	0.16%	74
2014 Q1	$1.94M	Sell	37,672 -240	-0.6%	-$12.1K	0.2%	68
2013 Q4	$2M	Sell	37,912 -1,759	-4%	-$86.5K	0.21%	68
2013 Q3	$1.77M	Buy	39,671 +210	+0.5%	+$9.31K	0.19%	75
2013 Q2	$1.63M	Buy	+39,461	New	+$1.73M	0.17%	79

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Estabrook Capital Management's ABBV Position: Q1 2026 in Review

Estabrook Capital Management held its AbbVie (ABBV) position steady in Q1 2026 at 12,721 shares worth $2.77M. The position accounts for 0.4% of the portfolio, ranked #55.

Estabrook Capital Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.02M in Q3 2024. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Estabrook Capital Management held 12,721 shares of AbbVie worth $2.77M as of Q1 2026.
Estabrook Capital Management left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.4% of Estabrook Capital Management's portfolio in Q1 2026, its #55 holding.
Estabrook Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Estabrook Capital Management's AbbVie position peaked at $3.02M in Q3 2024.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Estabrook Capital Management's 13F filing for Q1 2026, filed 14 May 2026.